Abstract 3725
Background
Photoimmunotherapy (PIT) is a platform technology that utilizes a photoactivatable dye conjugated to a cancer-targeting antibody. RM-1929 is composed of anti-EGFR antibody cetuximab and IRDye® 700DX. Binding of RM-1929 to EGFR followed by tumor illumination with non-thermal red light elicits rapid necrosis of EGFR-expressing cancer cells. RM-1929 PIT treatment was evaluated in a Phase 1/2a trial in patients with rHNSCC who failed multiple standard of care therapies, and demonstrated a favorable safety profile and resulted in positive response rates (Cognetti et al. ASCO 2019). Here we report preliminary data from exploratory biomarker studies from this study.
Methods
Phase 1 included 9 patients and Phase 2a cohort 30 patients. Pre-treatment biopsies and blood were collected within 12 months and 2 weeks prior to treatment, respectively. Post-treatment biopsies and blood samples were collected after cycle 1 and multiple time points during treatment cycles, respectively. EGFR and PD-L1 IHC expression and plasma cytokines levels were measured. PBMCs were phenotyped using innate and adaptive immune-marker panels.
Results
In 25 patients with pre-treatment biopsies, no trend was observed between EGFR expression and best target tumour response. In 12 patients for which pre- and post-treatment biopsies were available, EGFR expression was maintained in residual tumour after RM-1929 PIT treatment. Additionally, treatment was associated with induction of PD-L1 expression in tumour and immune cells in 10 out of 12 cases. In 13 samples tested, elevated baseline plasma cytokine levels were observed in 4 of 7 responders (3 of 4 CR and 1 of 3 PR) and 1 of 6 non-responders (1 of 5 SD and 0 of 1 PD). Immunophenotyping of whole blood showed systemic induction of innate and adaptive immunity (e.g. NK cells, cytokines, lymphocytes, monocytes, CD4 and CD8 T-cells) after treatment in 15 of 18 patients.
Conclusions
Biomarker analysis in this limited data set provided evidence of potential activation of innate and adaptive immunity following RM-1929 PIT treatment. Further evaluation of these biomarkers will be conducted in a Phase 3 trial (NCT03769506).
Clinical trial identification
NCT02422979.
Editorial acknowledgement
Legal entity responsible for the study
Rakuten Medical, Inc.
Funding
Rakuten Medical, Inc.
Disclosure
J.D. Bui: Advisory / Consultancy: Rakuten Medical, Inc.; Advisory / Consultancy, Research grant / Funding (self): Ignyta, Inc.; Shareholder / Stockholder / Stock options: Paramita Therapeutics. N. Suslov: Shareholder / Stockholder / Stock options, Full / Part-time employment: Rakuten Medical, Inc. D. Yadav: Shareholder / Stockholder / Stock options, Full / Part-time employment: Rakuten Medical, Inc. J. Fong: Shareholder / Stockholder / Stock options, Full / Part-time employment: Rakuten Medical, Inc. E. Sun: Shareholder / Stockholder / Stock options, Full / Part-time employment: Rakuten Medical, Inc. M. Haedo: Shareholder / Stockholder / Stock options, Full / Part-time employment: Rakuten Medical, Inc. M. Garcia-Guzman: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Rakuten Medical, Inc.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract